Page last updated: 2024-11-13

pervanadate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pervanadate: from a mixture of orthovanadate and hydrogen peroxide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID24978557
MeSH IDM0206229

Synonyms (5)

Synonym
pov ,
pervanadate
trisodium trioxido(oxo)vanadium - hydrogen peroxide (1:3)
DTXSID2041092
trisodium;hydrogen peroxide;trioxido(oxo)vanadium

Research Excerpts

Overview

Pervanadate is a potent inhibitor of protein tyrosine phosphatase. It has been observed to induce proliferation in C3H10T1/2 mouse fibroblasts.

ExcerptReferenceRelevance
"Pervanadate is a potent inhibitor of protein tyrosine phosphatase which has been observed here to induce proliferation in C3H10T1/2 mouse fibroblasts."( Pervanadate elicits proliferation and mediates activation of mitogen-activated protein (MAP) kinase in the nucleus.
Freyermuth, S; Krady, MM; Malviya, AN; Rogue, P, 1997
)
2.46

Effects

ExcerptReferenceRelevance
"Pervanadate has been shown to rapidly increase the level of tyrosine phosphorylation in intact cells. "( Pervanadate simulates the effects of interleukin-2 (IL-2) in human T cells and provides evidence for the activation of two distinct tyrosine kinase pathways by IL-2.
Erwin, R; Evans, GA; Farrar, WL; Garcia, GG; Howard, OM, 1994
)
3.17

Treatment

Pervanadate treatment neutralized the inhibitory activity of Bh on VEGF signalling. Bh infection may activate a phosphatase that alleviates VEGFR2 phosphorylation. In pervanadate (PV)-treated B cells, multiple proteins are tyrosine phosphorylated upon expression of the BCR.

ExcerptReferenceRelevance
"Pervanadate treatment neutralized the inhibitory activity of Bh on VEGF signalling, suggesting that Bh infection may activate a phosphatase that alleviates VEGFR2 phosphorylation."( The Bartonella henselae VirB/Bep system interferes with vascular endothelial growth factor (VEGF) signalling in human vascular endothelial cells.
Dehio, C; Mistl, C; Quebatte, M; Scheidegger, F, 2011
)
1.09
"Pervanadate treatment reversed the β-escin sodium-induced downregulation of STAT3 and STAT1."( β-Escin sodium inhibits inducible nitric oxide synthase expression via downregulation of the JAK/STAT pathway in A549 cells.
Cui, JR; Ji, DB; Liu, JT; Ran, FX; Xu, B, 2011
)
1.09
"In pervanadate (PV)-treated B cells, multiple proteins are tyrosine phosphorylated upon expression of the BCR, indicating that the BCR can signal in an antigen-independent fashion."( BCR mutants deficient in ligand-independent and more sensitive for ligand-dependent signaling.
Gimborn, K; Huber, M; Pracht, C; Reth, M, 2002
)
0.83
"In pervanadate (PV)-treated B cells, comparable pathways are activated on expression of the BCR, indicating that the BCR can signal in an antigen-independent fashion as well."( B-cell signal transduction: tyrosine phosphorylation, kinase activity, and calcium mobilization.
Brummer, T; Elis, W; Huber, M; Reth, M, 2004
)
0.84
"Pervanadate treatment of a mouse T-cell hybridoma cell line overexpressing an activated form of p56lck was shown to result in tyrosine phosphorylation of CD45. "( Association of CD45 with Lck and components of the Ras signalling pathway in pervanadate-treated mouse T-cell lines.
Branton, PE; Fournel, M; Lee, JM; Veillette, A, 1996
)
1.97
"Pervanadate treatment of the cells in suspension state resulted in highly elevated levels of cellular protein tyrosine phosphorylation accompanied by loss of beta 1 integrin-mediated adhesion to substrata (i.e., collagen and laminin)."( Differential role of protein tyrosine phosphorylation/dephosphorylation in affinity regulation of beta 1 and beta 3 integrin in human fibroblasts.
Saito, Y; Takagi, J, 1995
)
1.01
"Pervanadate treatment causes a time- and concentration-dependent increase in the tyrosine phosphorylation of Kv1.3."( Tyrosine phosphorylation of the Kv1.3 potassium channel.
Fadool, DA; Holmes, TC; Levitan, IB, 1996
)
1.02
"Thus pervanadate treatment of cells results in two effects of syndecan-1: (i) phosphorylation of one or more of its tyrosines via the action of a cytoplasmic kinase(s) and (ii) cleavage and release of the ectodomain into the medium, producing a C-terminal fragment containing the transmembrane/cytoplasmic domain."( Pervanadate activation of intracellular kinases leads to tyrosine phosphorylation and shedding of syndecan-1.
Lebakken, CS; McCarthy, J; Ott, VL; Rapraeger, AC; Reiland, J; Yeaman, C, 1996
)
2.19
"Pervanadate treatment also led to an increase in overall protein tyrosine phosphorylation and phosphorylation of Stat1, as well as the subsequent increase in ICAM-1 mRNA and cell surface protein levels."( Pervanadate mimics IFNgamma-mediated induction of ICAM-1 expression via activation of STAT proteins.
Caughman, SW; Duff, JL; Naik, SM; Paxton, LL; Quinlan, KL, 1997
)
2.46
"Pervanadate treatment of the cells potentiates and prolongs the increased phosphorylation."( Hypotonic-stimulated taurine efflux in skate erythrocytes: regulation by tyrosine phosphatase activity.
Davis-Amaral, EM; Goldstein, L; Leibowitz, KL; Musch, MW, 1998
)
1.02
"Pervanadate treatment increases keratin solubility and also indirectly increases K8/18 serine phosphorylation at several known sites, some of which were previously shown to be associated with EGF stimulation, extracellular signal-regulated kinase (ERK), or p38 kinase activation."( Pervanadate-mediated tyrosine phosphorylation of keratins 8 and 19 via a p38 mitogen-activated protein kinase-dependent pathway.
Feng, L; Liao, J; Omary, MB; Zhou, X, 1999
)
2.47
"Pervanadate treatment of N2a neuroblastoma cells resulted in tyrosine phosphorylation and association of endogenous APP and Shc A."( Tyrosine phosphorylation of the beta-amyloid precursor protein cytoplasmic tail promotes interaction with Shc.
D'Adamio, L; Pelicci, G; Pelicci, PG; Roncarati, R; Tarr, PE, 2002
)
1.04
"Pervanadate treatment activated p38 MAPK in a dose-and time-dependent manner."( The p38 mitogen-activated protein kinase is involved in stress-induced phospholipase D activation in vascular smooth muscle cells.
Kim, EG; Min, DS; Shin, EY, 2002
)
1.04
"Treatment with pervanadate caused internalisation of kAE1 from the plasma membrane, but treatment with high concentrations of bicarbonate did not, because of the hypertonicity of the solution."( Human kidney anion exchanger 1 localisation in MDCK cells is controlled by the phosphorylation status of two critical tyrosines.
Brown, AC; Mawby, WJ; Toye, AM; Williamson, RC, 2008
)
0.69
"Treatment with pervanadate/H2O2 does not result in receptor crosslinking, yet the pattern of protein phosphorylation is similar to that observed after BCR stimulation by antigen."( Evidence for a preformed transducer complex organized by the B cell antigen receptor.
Larbolette, O; Reth, M; Wienands, J, 1996
)
0.63
"Treatment with pervanadate or phorbol myristate acetate inhibits PLD more in HEK 293 cells overexpressing alpha-synuclein than in control cells."( alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells.
Ahn, BH; Chang, JS; Choi, JY; Chung, KC; Hahn, SJ; Jo, YH; Kim, MS; Kim, SY; Kwon, TK; Lee, MY; Lee, YH; Min, DS; Rhim, H; Sung, YM; Wolozin, B; Yoon, SH, 2002
)
0.89

Toxicity

ExcerptReferenceRelevance
" Adverse events (AEs) were generally mild to moderate, with no AE-driven study drug discontinuations noted."( Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers.
Di Paolo, JA; Jin, F; Kearney, BP; Ramanathan, S; Robeson, M; Shao, L; Sharma, S, 2017
)
0.46

Pharmacokinetics

ExcerptReferenceRelevance
" Entospletinib displayed a median plasma half-life of 9-15 h; entospletinib exposures reached a plateau at ≥600 mg twice daily (likely due to solubility-limited absorption) and provided >90% CD63 inhibition at peak concentrations and >60% inhibition at trough concentrations (corresponding pSYK inhibition of >70 and >50%)."( Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers.
Di Paolo, JA; Jin, F; Kearney, BP; Ramanathan, S; Robeson, M; Shao, L; Sharma, S, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (359)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's152 (42.34)18.2507
2000's174 (48.47)29.6817
2010's30 (8.36)24.3611
2020's3 (0.84)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.92 (24.57)
Research Supply Index5.91 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index46.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.27%)5.53%
Reviews2 (0.54%)6.00%
Case Studies1 (0.27%)4.05%
Observational1 (0.27%)0.25%
Other362 (98.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]